TGF-β antagonists: Why suppress a tumor suppressor?
J. Clin. Invest. Rosemary J. Akhurst, et al. 109:1533 doi:10.1172/JCI15970 [Go to this article.]

Figure 2
The balance between the autocrine homeostatic and tumor-progressing activities of TGF-β is perturbed by activation of oncogenic signaling pathways. As tumor progression proceeds, the homeostatic branch of TGF-β action becomes increasingly compromised, and tumors secrete more TGF-β1, thus exacerbating tumor progression.